Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Cardiology

Prognosis, Risk Scores, and Long-Term Surveillance

At a Glance

Chagas cardiomyopathy can stay silent for years, so long-term surveillance matters. Rassi and SaMi-Trop scores, cardiac MRI scar assessment, EKGs, and echocardiograms help clinicians estimate risk and tailor monitoring, but no single score determines treatment.

For many people, Chagas disease is a life-long journey that requires a shift in perspective. It is less about a “cure” and more about “vigilance” [1]. Because the disease progresses so slowly, the goal of long-term care is to catch very early changes in the heart muscle before they become serious problems.

By using specialized “risk scores” and advanced imaging, you and your doctor can create a personalized roadmap for your health over the next 10 to 20 years.

Predicting the Future: Risk Scores

Doctors use specific scoring systems to understand how the disease might behave in your body. These tools help them predict risk and guide shared decision-making regarding testing or treatments like an ICD (defibrillator) [2][3].

The Rassi Score

The Rassi Score is one of the most widely used tools for patients who already have established Chagas heart disease [3]. It looks at six key clinical factors to predict long-term mortality risk:

  1. NYHA Class III/IV: Advanced heart failure symptoms (like shortness of breath with mild activity).
  2. Cardiomegaly: An enlarged heart visible on an X-ray [4].
  3. Low QRS Voltage: Specific patterns of weak electrical signals on an EKG.
  4. Left-Ventricular Systolic Dysfunction: How well the heart’s main chamber is pumping.
  5. Nonsustained Ventricular Tachycardia: Runs of fast heartbeats on a 24-hour monitor [2].
  6. Male Sex.

Based on these points, you are categorized into low, intermediate, or high mortality risk. While it is an excellent tool for prognosis, a low or high score does not automatically dictate your medication changes or ICD placement on its own; it supports shared decision-making [3][2].

The SaMi-Trop Score

Another tool, the SaMi-Trop score, focuses on predicting your health over a shorter 2-year window for defined cohorts of patients with established cardiomyopathy [5]. It uses your age, heart rate, EKG findings, and a specific blood test called NT-proBNP, which measures “stress” on the heart muscle [5]. This score is especially helpful for doctors in areas where advanced imaging might not be immediately available [5].

The Power of the Cardiac MRI

While risk scores are helpful, a cardiac MRI provides an independent look at your heart’s tissue. The key thing doctors look for is myocardial fibrosis (scar tissue) using Late Gadolinium Enhancement (LGE) [6].

Research shows that the more scar tissue present on an MRI, the higher the risk of future rhythm problems [6][7]. While scar burden helps assess risk, it does not by itself predict exactly what will happen or determine an ICD placement; it supports clinical assessment [8].

Living with the “Silent” Disease

Living with a condition that can remain silent for decades can take a psychological toll. It is common for patients to experience:

  • “Scan Anxiety”: Feeling nervous or overwhelmed in the days leading up to a heart test [9].
  • Stigma and Shame: Feeling like you cannot talk about your diagnosis because of misunderstandings about how Chagas is spread [10][11].
  • Depression and Anxiety: Chronic conditions are linked to higher rates of low mood and persistent worry [12][13].

Strategies for Long-Term Success

  • Normalize Monitoring: Try to view your yearly EKG the same way you view a dental cleaning—it is a routine part of staying healthy, not a sign that something is wrong.
  • Build a Support System: Family support and spirituality are powerful resources that help many patients stay engaged with their care [14][15].
  • Advocate for Your Care: If you face barriers like language, cost, or work schedules, ask your clinic for a “care navigator” or social worker who can help you stay connected to your medical team [16][17].

A Chagas diagnosis requires vigilance rather than relying on a cure [1]. For many in the indeterminate phase, it means decades of a normal, active life. For those with established cardiomyopathy, it requires individualized care supported by the safety net of regular medical surveillance [18].

Common questions in this guide

What does the Rassi Score tell me about Chagas cardiomyopathy?
The Rassi Score combines six clinical findings—heart failure severity, an enlarged heart, low EKG voltage, reduced pumping strength, short runs of fast ventricular rhythms, and sex—to group people with established Chagas heart disease into low-, intermediate-, or high-risk categories. It estimates long-term mortality risk. The result supports conversations about monitoring and treatment but does not by itself determine medication changes or ICD placement.
What is the SaMi-Trop score used for?
The SaMi-Trop score estimates risk over about two years in defined groups of people with established Chagas cardiomyopathy. It uses age, heart rate, EKG findings, and NT-proBNP, a blood marker that reflects stress on the heart. It can be useful when advanced imaging is not readily available.
Does scarring on a cardiac MRI mean I will have an arrhythmia?
More myocardial fibrosis, or scar tissue, on cardiac MRI is associated with a higher risk of future rhythm problems. However, the amount of scar does not predict exactly what will happen and does not alone determine whether an ICD is needed. Clinicians interpret it with symptoms, EKGs, heart function, and other findings.
How often should I have an EKG or echocardiogram with Chagas cardiomyopathy?
There is no single schedule for everyone with Chagas cardiomyopathy. Timing depends on whether the disease is in an indeterminate or established phase, your symptoms, heart function, rhythm findings, and previous results. Your cardiology team should set an individualized schedule for regular EKGs and echocardiograms.
What might make my doctor consider an ICD or change my medications?
Changes in heart pumping function, new or worsening heart failure symptoms, or ventricular rhythm abnormalities may prompt reassessment. EKG or monitor findings such as nonsustained ventricular tachycardia and the overall clinical picture can inform the discussion. A risk score or MRI scar finding alone does not automatically require an ICD or a medication change.
How can I manage anxiety and practical challenges during long-term Chagas monitoring?
Scan anxiety, low mood, worry, and stigma can make long-term care harder. Treating routine monitoring as a normal part of staying healthy, talking with trusted family or friends, and using spiritual or community support may help. A care navigator or social worker can assist with language, transportation, cost, or work-related barriers.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my clinical findings, what is my 'Rassi score,' and how does it help guide my monitoring plan over the next few years?
  2. 2.If my cardiac MRI showed scarring (late gadolinium enhancement), how does that change the way you assess my risk for arrhythmias?
  3. 3.How often should we repeat my echocardiogram and EKG based on my current stage of the disease?
  4. 4.What specific changes on my next EKG would prompt us to change my medications or consider a device like an ICD?
  5. 5.Are there local support groups or resources for patients living with Chagas disease in this area?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    The multidimensional comprehension of Chagas disease. Contributions, approaches, challenges and opportunities from and beyond the Information, Education and Communication field.

    Sanmartino M, Forsyth CJ, Avaria A, et al.

    Memorias do Instituto Oswaldo Cruz 2022; (117()):e200460 doi:10.1590/0074-02760200460.

    PMID: 35674539
  2. 2

    Amiodarone or Implantable Cardioverter-Defibrillator in Chagas Cardiomyopathy: The CHAGASICS Randomized Clinical Trial.

    Martinelli-Filho M, Marin-Neto JA, Scanavacca MI, et al.

    JAMA cardiology 2024; (9(12)):1073-1081 doi:10.1001/jamacardio.2024.3169.

    PMID: 39356542
  3. 3

    Enhancing risk assessment in Chagas cardiomyopathy: Electrophysiology study stratified by Rassi score.

    Costa IP, Lima NA, Vieira JL, et al.

    International journal of cardiology 2024; (417()):132553 doi:10.1016/j.ijcard.2024.132553.

    PMID: 39278552
  4. 4

    Correlation between Cardiomegaly on Chest X-Ray and Left Ventricular Diameter on Echocardiography in Patients with Chagas Disease.

    Ramos MRF, Moreira HT, Volpe GJ, et al.

    Arquivos brasileiros de cardiologia 2021; (116(1)):68-74 doi:10.36660/abc.20190673.

    PMID: 33566967
  5. 5

    Risk Score for Predicting 2-Year Mortality in Patients With Chagas Cardiomyopathy From Endemic Areas: SaMi-Trop Cohort Study.

    Di Lorenzo Oliveira C, Nunes MCP, Colosimo EA, et al.

    Journal of the American Heart Association 2020; (9(6)):e014176 doi:10.1161/JAHA.119.014176.

    PMID: 32157953
  6. 6

    Long-Term Prognostic Value of Myocardial Fibrosis in Patients With Chagas Cardiomyopathy.

    Senra T, Ianni BM, Costa ACP, et al.

    Journal of the American College of Cardiology 2018; (72(21)):2577-2587 doi:10.1016/j.jacc.2018.08.2195.

    PMID: 30466515
  7. 7

    Cardiac Magnetic Resonance-Verified Myocardial Fibrosis in Chagas Disease: Clinical Correlates and Risk Stratification.

    Uellendahl M, Siqueira ME, Calado EB, et al.

    Arquivos brasileiros de cardiologia 2016; (107(5)):460-466 doi:10.5935/abc.20160168.

    PMID: 27982271
  8. 8

    Multimodality imaging evaluation of Chagas disease: an expert consensus of Brazilian Cardiovascular Imaging Department (DIC) and the European Association of Cardiovascular Imaging (EACVI).

    Nunes MCP, Badano LP, Marin-Neto JA, et al.

    European heart journal. Cardiovascular Imaging 2018; (19(4)):459-460n doi:10.1093/ehjci/jex154.

    PMID: 29029074
  9. 9

    Health-related quality-of-life associated with Chagas disease in Argentina and Spain.

    Ramponi F, Sartor P, Pinazo MJ, et al.

    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2026; (164()):108363 doi:10.1016/j.ijid.2025.108363.

    PMID: 41478338
  10. 10

    Anthropological study on Chagas Disease: Sociocultural construction of illness and embodiment of health barriers in Bolivian migrants in Rome, Italy.

    Castaldo M, Cavani A, Segneri MC, et al.

    PloS one 2020; (15(10)):e0240831 doi:10.1371/journal.pone.0240831.

    PMID: 33064748
  11. 11

    The role of the first level of health care in the approach to Chagas disease in a non-endemic country.

    Iglesias-Rus L, Romay-Barja M, Boquete T, et al.

    PLoS neglected tropical diseases 2019; (13(12)):e0007937 doi:10.1371/journal.pntd.0007937.

    PMID: 31841503
  12. 12

    Anxiety, depression, and memory loss in Chagas disease: a puzzle far beyond neuroinflammation to be unpicked and solved.

    Lannes-Vieira J, Vilar-Pereira G, Barrios LC, Silva AA

    Memorias do Instituto Oswaldo Cruz 2023; (118()):e220287 doi:10.1590/0074-02760220287.

    PMID: 37018799
  13. 13

    Shared neuroimmune and oxidative pathways underpinning Chagas disease and major depressive disorder.

    Duarte-Silva E, Maes M, Macedo D, et al.

    Translational psychiatry 2020; (10(1)):419 doi:10.1038/s41398-020-01105-9.

    PMID: 33268766
  14. 14

    Development of an ICF Core Set for adults with Chagas disease: a qualitative study capturing patients' perspective on functioning.

    Ottone NCS, Costa HS, Souza SG, et al.

    Revista da Sociedade Brasileira de Medicina Tropical 2026; (59()):e04012025 doi:10.1590/0037-8682-0401-2025.

    PMID: 42307393
  15. 15

    Social determinants in the access to health care for Chagas disease: A qualitative research on family life in the "Valle Alto" of Cochabamba, Bolivia.

    Jimeno I, Mendoza N, Zapana F, et al.

    PloS one 2021; (16(8)):e0255226 doi:10.1371/journal.pone.0255226.

    PMID: 34383775
  16. 16

    Bridging the critical gap between infectious disease blood donation screening and connection to healthcare services: the American Chagas disease example.

    Lynn MK, Parker M, Stramer SL, et al.

    Journal of public health policy 2025; (46(1)):168-179 doi:10.1057/s41271-024-00539-5.

    PMID: 39695217
  17. 17

    Barriers to Chagas Disease Screening among Primary Care Providers in the United States.

    Carrion MN, Kienle RM, Bourque D, et al.

    The American journal of tropical medicine and hygiene 2026; (114(5)):857-864 doi:10.4269/ajtmh.25-0559.

    PMID: 41806373
  18. 18

    Risk of Chronic Cardiomyopathy Among Patients With the Acute Phase or Indeterminate Form of Chagas Disease: A Systematic Review and Meta-analysis.

    Chadalawada S, Sillau S, Archuleta S, et al.

    JAMA network open 2020; (3(8)):e2015072 doi:10.1001/jamanetworkopen.2020.15072.

    PMID: 32865573

This page is for informational purposes only and does not constitute medical advice. Your cardiology team should interpret your Rassi or SaMi-Trop score, cardiac MRI, and surveillance plan for your individual situation.

Get notified when new evidence is published on Chagas cardiomyopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.